Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India

Table 3 Treatment features and outcomes of primary vs secondary intra-arterial chemotherapy in 17 eyes

IAC features	Primary IAC (n = 9)	Secondary IAC with intravitreal chemotherapy (n = 8)	P value	Total
Median number of cycles	1 (1-3)	2 (1-3)	0.403	1.7	Mann Whitney U test
Melphalan only	2	1	1.000	3
Melphalan + topotecan	6	6		12	Fisher’s exact test
Melphalan + topotecan + carboplatin	1	1		2
Melphalan [median (range)]	5 (3-12.5)	5 (5-12.5)	0.33	5 (3-12.5)
Topotecan [median (range)]	1 (1-3)	1 (1-3)	1	1 (1-3)
Carboplatin [median (range)]	30 (-)	30 (-)	-	30 (-)
Intravitreal chemotherapy features
Mean number of injections [median (range)]	-	3 (1-5)	-	3 (1-5)
Melphalan only [median (range)]	-	1 (16)		1 (16)
Topotecan only [median (range)]	-	2 (34)		2 (34)
Melphalan + topotecan [median (range)]	-	3 (50)		3 (50)
Systemic chemotherapy
Mean number of cycles [median (range)]	-	8 (6-11)	-	8 (6-11)
Brachytherapy [median (range)]	-	1		1
Outcomes
Follow-up months [median (range)]	20 (1-72)	28 (10-72)	0.385	30.17 (1-72)	Mann Whitney U test
Tumor control	8 (88)	7 (88)	1.00	15 (88)	Fisher’s exact test
Tumor control per ICRB
Group B	2	3	0.72	5	Fisher’s exact
Group C	0	1		1
Group D	2	1		3
Group E	4	2		6
Enucleation per ICRB group
Group B	0	0	-	0
Group C	0	0		0
Group D	0	1		1
Group E	1	0		1
Visual acuity of salvaged eyes	n = 8	n = 7		15
> 6/60 [median (range)]	2 (25)	2 (28.6)	1	4	Fisher’s exact
< 6/60 [median (range)]	6 (75)	5 (71.4)		11

Data were presented as n (%). IAC: Intra-arterial chemotherapy; ICRB: International classification of retinoblastoma.